Free Trial
NASDAQ:CDIO

Cardio Diagnostics 8/12/2024 Earnings Report

Cardio Diagnostics logo
$1.98 +0.02 (+1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$1.98 0.00 (0.00%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics EPS Results

Actual EPS
-$1.80
Consensus EPS
-$3.90
Beat/Miss
Beat by +$2.10
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.13 million
Beat/Miss
Missed by -$120.00 thousand
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cardio Diagnostics' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

Cardio Diagnostics Earnings Headlines

Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

View Cardio Diagnostics Profile